目的 评价灵宝护心丹治疗心动过缓型心律失常的有效性和安全性。方法 选取2020年11月—2022年12月上海市第六人民医院收治的窦性心动过缓患者100例，随机分为对照组（50例）和治疗组（50例）。对照组患者口服二羟丙茶碱片，100 mg/次，3次/d；治疗组患者口服灵宝护心丹，4丸/次，3次/d。两组患者治疗12周。观察两组患者临床疗效，比较治疗前后两组患者中医证候评分，动态心电图指标平均心率、总心率和最慢心率，及不良反应情况。结果 治疗后，对照组和治疗组总有效率分别为91.11%、97.87%，两组比较差异具有统计学意义（P＜0.05）。治疗第4、8、12周后，两组中医症候评分均显著降低（P＜0.05）；治疗组患者中医证候评分均低于同期对照组（P＜0.05）。治疗第4、8、12周后，两组平均心率、总心率和最慢心率均显著提高（P＜0.05）；治疗8、12周后，治疗组平均心率、总心率和最慢心率显著高于同期对照组（P＜0.05）。治疗组不良反应总发生率（2.13%）显著低于对照组（11.11%，P＜0.05）。结论 灵宝护心丹对心动过缓型心律失常患者具有较好疗效，且安全性较好，长期使用优于二羟丙茶碱。

Objective To evaluate the clinical efficacy and safety of Lingbao Huxindan in treatment of bradycardia arrhythmia. Methods Patients (100 cases) with bradycardia arrhythmia in Shanghai Sixth People's Hospital from November 2020 to December 2022 were randomly divided into control (50 cases) and treatment (50 cases) group. Patients in the control group were po administered with Diprophylline Tablets, 100 mg/time, three times daily. Patients in the treatment group were po administered with Lingbao Huxindan on the basis of the control group, 4 pills/time, three time daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluations were evaluated, the TCM syndrome scores, dynamic electrocardiogram indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate was 97.87% in the treatment group and 91.11% in the control group, the difference between the two groups was statistically significant (P < 0.05). After 4, 8 and 12 weeks of treatment, TCM symptom scores in both groups were significantly decreased (P < 0.05). The TCM syndrome scores in the treatment group were lower than those in the control group (P < 0.05). After 4, 8 and 12 weeks of treatment, the mean heart rate, total heart rate and minimum heart rate of the two groups were significantly increased (P < 0.05). After 8 and 12 weeks of treatment, the mean heart rate, total heart rate and minimum heart rate in the treatment group were significantly higher than those in the control group (P < 0.05). The total incidence of adverse reactions in the treatment group (2.13%) was significantly lower than that in the control group (11.11%, P < 0.05). Conclusion Lingbao Huxindan has a good curative effect and safety in patients with bradycardia arrhythmias, and its long-term use is better than that of dihydroxypropylline.

R972